Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

A. Tutt

View on Semantic Scholar

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

PURPOSE VIOLETTE (NCT03330847) assessed olaparib alone or with ceralasertib (ATR inhibitor) or adavosertib (WEE1 inhibitor) as second-/third-line treatment in three molecular strata of patients with previously treated, PARP inhibitor-naïve, advanced triple-negative breast cancer (TNBC). PATIENTS AND METHODS Patients...

A. Tutt, Z. Nowecki, R. Szoszkiewicz et al. · 0 citations
Open access Oct 2026

A genome-scale adaptation map identifies the FANCM-RMI1/2 complex as an opposing modulator of cell fitness upon BRCA1 or BRCA2 loss.

Cancer cells lacking BRCA1 or BRCA2 must adapt to proliferate despite pervasive genomic instability. To delineate BRCA1- and BRCA2-specific adaptation landscapes, we developed an isogenic screening platform enabling acute depletion of either protein. Genetic interaction profiling revealed hundreds of genes with shared,...

François Dossin, Mikaël Attia, Fabricio Montero-Zúñiga et al. · 0 citations
Clinical trial Open access Sep 2026

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

Successful cancer immunotherapy requires not only tumor cell killing but also the activation of innate and adaptive immune responses. The inhibitor of apoptosis (IAP) proteins cIAP1, cIAP2 and XIAP act as key suppressors of RIPK1-driven immunogenic cell death, thereby enabling tumor immune evasion and limiting the effe...

C. Tiu, Wing Yau, T. Tenev et al. · 0 citations
Open access Aug 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

BACKGROUND The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...

J. Garber, D. Cameron, C. Campbell et al. · 1 citation
Open access Aug 2026

Mitotic single-stranded DNA suppression by DDIAS.

It is reported that DDIAS is a DNA-binding effector of the CIP2A pathway in human cells and proposed that DDIAS defines a mitotic DNA repair system downstream of CIP2A that mitigates the threat of mitotic ssDNA for genome integrity.

Yibo Xue, Faisal Bin Rashed, Daniel Y. L. Mao et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.